Company Profile

Accelalox Inc
Profile last edited on: 9/28/2016      CAGE: 5BJ11      UEI: T4EKFBZGN975

Business Identifier: Oral and small-molecule therapies to treat muscle and bone conditions
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

325 Sharon Park Drive Suite 310
Menlo Park, CA 94025
   (650) 854-1465
Location: Single
Congr. District: 18
County: San Mateo

Public Profile

Accelalox Inc. is developing therapies to treat musculoskeletal conditions. Initial development program ifocused on an oral, small-molecule therapy to significantly accelerate and enhance bone healing. This therapy will be used for bone fractures and spinal fusions to improve patient outcomes through accelerated healing and reduced complications

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2010 1 NIH $228,827
Project Title: Pharmacological Method To Accelerate Bone Fracture Healing

Key People / Management

  Julia A O’Connor -- Chief Executive Officer and Founder

  J Patrick O'Connor -- Chief Scientific Officer and Founder

Company News

There are no news available.